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Abstract
Introduction: To understand the role of two interacting proteins LIMD1 and pRB in development of head and
neck squamous cell carcinoma (HNSCC), alterations of these genes were analyzed in 25 dysplastic head and neck
lesions, 58 primary HNSCC samples and two HNSCC cell lines.
Methods: Deletions of LIMD1 and RB1 were analyzed along with mutation and promoter methylation analysis of
LIMD1. The genotyping of LIMD1 linked microsatellite marker, hmlimD1, was done to find out any risk allele. The
mRNA expression of LIMD1 and RB1 were analyzed by Q-PCR. Immunohistochemical analysis of RB1 was performed.
Alterations of these genes were correlated with different clinicopathological parameters.
Results: High frequency [94% (78/83)] of LIMD1 alterations was observed in the samples studied. Compare to
frequent deletion and methylation, mutation of LIMD1 was increased during tumor progression (P = 0.007). Six
novel mutations in exon1 and one novel intron4/exon5 splice-junction mutation were detected in LIMD1 along
with a susceptible hmlimD1 (CA)20 allele. Some of these mutations [42% (14/33)] produced non-functional proteins.
RB1 deletion was infrequent (27%). Highly reduced mRNA expression of LIMD1 (25.1 ± 19.04) was seen than RB1
(3.8 ± 8.09), concordant to their molecular alterations. The pRB expression supported this data. Tumors with LIMD1
alterations in tobacco addicted patients without HPV infection showed poor prognosis. Co-alterations of these
genes led the worse patients’ outcome.
Conclusions: Our study suggests LIMD1 inactivation as primary event than inactivation of RB1 in HNSCC
development.
Introduction
Head and neck squamous cell carcinoma (HNSCC) is an
aggressive malignancy, accounts for 30-40% of all cancer
types in Indian subcontinent [1]. Tobacco, betel nut leaf
quid, alcohol, HPV-16/18 infection are well recognized
carcinogenic risk factors for development of this cancer
[2]. Despite significant progress in understanding mole-
cular genetic events underlying the development of
HNSCC, details mechanisms still remain unknown [3,4].
Suppression of tumorigenicity of oral cancer cell lines
following introduction of chromosome 3p in microcell
hybrid system, suggested the presence of at least one
tumor suppressor gene (TSG) in this chromosome asso-
ciated with HNSCC development [5]. Our previous
study in HNSCC of Indian patients showed high fre-
quency of loss of heterozygosity (LOH) in chromosomal
(chr.) 3p21.31 region and its association with develop-
ment of early dysplastic lesions [6]. Among the multiple
TSGs localized in chr.3p21.31, our recent study demon-
strated one of the candidate TSGs, LIMD1 alteration
(deletion/methylation) was significantly associated with
mild dysplastic lesions of head and neck [7]. Downregu-
lation of this gene observed in HNSCC and lung cancer
[7,8]. A recent study emphasized LIMD1 as a critical
TSG showing frequent downregulation in expression
due to genetic and epigenetic modification in human
lung cancer [9]. But no coding region mutation of this
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gene was observed in lung cancer. Also a polymorphic
dinucleotide cytosine-adenine [d(CA)] microsatellite
repeat, hmlimD1 (Accession number EU125867) was
located at 15 bp upstream of LIMD1 gene [7]. Suscept-
ibility allele of this gene, if any, for HNSCC develop-
ment was unknown. LIMD1 has 8 exons and encodes a
676 amino acid protein, with a leucine-rich nuclear
export signal (NES) in its N-terminal Pre-LIM domain
and in C-terminus harboring three LIM domains having
nuclear localizing properties (NLS) [8-10]. It is a ZYXIN
family protein, having tandem zinc fingers in its LIM
domains facilitating protein-protein interactions [11].
LIMD1 was reported to inhibit cell growth and metas-
tases, partly mediated through either an interaction of
its N-terminal LEM domain (amino acid 18-68) with
barrier-to-autointegration (BAF), a component of SWI/
SNF chromatin-remodeling protein, or through interac-
tion of its part of proline-serine rich domain (amino
acid 326-608) with C-terminus of retinoblastoma pro-
tein, pRB (amino acid 763-928) followed by transcrip-
tional repression of E2F target genes [8]. This might be
due to the stabilization of pRB-E2F interaction. The reti-
noblastoma gene, RB1 was reported to be infrequently
altered in HNSCC [12,13]. Our previous study showed
RB1 gene deletions were mainly associated with later
stages in HNSCC development [14,15]. However, altera-
tions of LIMD1 and RB1 were not screened in same set
of samples to understand their association together in
development of the disease.
Thus in this study attempts have been made to analyze
the alterations of LIMD1 and RB1 in 25 dysplastic head
and neck lesions, 58 primary HNSCC samples and two
HNSCC cell lines. We have screened LIMD1 mutation in
the entire exon1 (1429 bp) and exon5 along with RB1
deletion and its protein expression (by immunohistochem-
istry, IHC) in the same set of samples. The frequency of
LIMD1 mutation was then compiled with our previously
reported [7] of its deletion, promoter methylation and
mutation (in the SNP rs267236 site in exon1) frequencies
in these samples for clinicopathological correlation. The
alterations of LIMD1 were also correlated with RB1 altera-
tions. A population-based case-control study was per-
formed to find out any risk allele of hmlimD1. Our data
demonstrated that inactivation of LIMD1 was primary
event than RB1 in development of HNSCC.
Materials and methods
Patients, controls and cell lines
A total of 37 dysplastic lesions and 110 HNSCC tumors
and their matched normal tissues were collected from
147 unrelated individuals after obtaining informed con-
sent from patients according to hospital authorities of
Chittaranjan National Cancer Institute and Cancer Cen-
ter & Welfare Home, Kolkata, India. All tumors were
graded and staged according to UICC TNM classifica-
tion [16]. Freshly operated tissues were taken for isola-
tion of DNA/RNA and immunohistochemical analysis.
Among these samples deletion/methylation/mutation
analysis of the genes was performed in 25 dysplastic
lesions (mild, n = 3; moderate, n = 9; severe, n = 13), 58
HNSCC samples (stageI, n = 8; stageII, n = 11; stageIII,
n = 21; stageIV, n = 18) and two HNSCC cell lines
Hep2, UPCI: SCC084. However, the total samples pool
was used for case-control study. Table 1 presented clini-
copathological information of patient (n = 147) and
unrelated controls (n = 187) having no previous and
present history of HNSCC. Blood samples were col-
lected from controls with informed consent, and Institu-
tional Ethical Board approved the study. All patients
and controls were an age and sex frequency-matched
ethnically similar caste population from eastern India.
Two HNSCC cell lines, Hep2 and UPCI: SCC084 were
obtained from National Centre for Cell Sciences, Pune,
India and from Prof. Susanne M. Gollin, University of
Pittsburgh, USA, respectively.
Microdissection and DNA Extraction
Cryosections (5 μm) were microdissected under dissect-
ing microscope (Leica MZ16, Germany) using surgical
knives to remove contaminant normal cells. Controls’
blood and samples containing >60% tumor cells were
taken for DNA isolation by phenol/chloroform extrac-
tion [17].
Mutation analysis
LIMD1 was screened for mutation in 25 dysplasias, 58
HNSCC samples and the two HNSCC cell lines by single
strand conformation polymorphism (SSCP) analysis using
[a-P32] dCTP [14]. For mutation analysis six sets of pri-
mers were designed to amplify whole exon1 and one set
for the exon5 including their respective intron/exon bor-
ders (see Additional file 1: Table S1). In these samples
deletion and promoter methylation of LIMD1 have already
been reported [7], along with mutation status in exon1 at
the SNP rs267236 site using LIMD1 Exon1.6 primer set
(see Additional file 1: Table S1) in the 77/85 samples. Elec-
trophoresis was done in 6% non-denaturing polyacryla-
mide gel with 10% glycerol at 2W for overnight and
autoradiographed on X-ray film (Kodak, USA). Samples
showing abnormal band shifts were sequenced using
Genetic Analyzer (PE Applied Biosystems Inc, USA).
Deletion analysis
Deletion mapping of RB1 was done in the same set of
25 dysplasias, 58 HNSCC samples and two HNSCC cell
lines (as mentioned in Mutation analysis) using one
intragenic microsatellite marker, D13S153 (intron2 of
RB1, 47.8 Mb from p-ter) [15].
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Genotyping of hmlimD1 microsatellite marker
Genotyping of hmlimD1 was carried out by amplifying d
(CA)n repeat in a standard polymerase chain reaction
(PCR) using [g-P32] ATP labeled forward primer. PCR
products were electrophoresed on 7% denaturing polya-
crylamide sequencing gel and autoradiographed [18].
Signal intensities of radio-labeled products were mea-
sured by densitometric scanner (Bio-Rad, USA). Ampli-
fied fragments ranged in size from 187-216 bp,
depending on the number of CA repeats within ampli-
fied region. Representative homozygote for (CA)17, (CA)
19, (CA)20, (CA)21, (CA)24 and (CA)32 genotypes were
sequenced using Genetic Analyzer (PE Applied Biosys-
tems Inc, USA) to validate CA repeats number.
mRNA expression analysis
The mRNA expression of LIMD1 and RB1 genes was ana-
lyzed by quantitative RT-PCR in paired primary HNSCC
samples (n = 24) and two HNSCC cell lines using primers
mentioned in Additional file 1: Table S1. The LIMD1
mRNA expression was already reported in 11 of the 24
HNSCC samples and the two cell lines [7]. Total RNA was
isolated from the samples using TRIzol reagent (Invitro-
gen, USA) and complementary-DNA (cDNA) was synthe-
sized using Random hexamer (Invitrogen, USA) and
M-MuLV Reverse Transcriptase (Sibenzyme, Russia).
Real-time quantification of LIMD1 and RB1 was per-
formed in 40 cycles on an ABI Prism 7500 using Power
SYBR Green PCR Master Mix (Applied Biosystems, USA)
Table 1 Characteristics of patients and controls
Controls(187) Sex*
Male, N(%) 157(83.9%)
Female,(N%) 30(16.1%)
Mean Age# 45.5 ± 5.2
HNSCC & Dysplastic lesions(147) Sex*
Male, N(%) 110(74.8%)
Female,(N%) 37(25.2%)
Mean Age# 52 ± 6.4
Lymp Node Positive 26(17.7%)
Lymp Node Negative 121(82.3%)
Tobacco User 103(70%)
Tobacco free 44(30%)
Alcohol User 13(8.8%)
Alcohol free 134(91.2%)
HNSCC (110) Oral Cavity tumors(85) Buccal Mucosa, N(%) 32(29.1%)
Tongue, N(%) 13(11.8%)
Cheek, N(%) 19(17.3%)
Lip, N(%) 3(2.7%)
Tonsil, N(%) 4(3.6%)
Palate, N(%) 2(1.8%)
Alveolus, N(%) 11(10%)
Vocal cord, N(%) 1(0.9%)
Laryngeal Tumors(12) & Larynx, N(%) 12(10.9%)
Nasopharyngeal Tumor(3) Nassopharynx, N(%) 3(2.7%)
Orofacial Tumors(10) Maxilla, N(%) 5(4.5%)
Mandible, N(%) 5(4.5%)
Histopathology(110) StageI 15(14%)
StageII 30(27%)
StageIII 34(31%)
StageIV 31(28%)
Dysplastic lesions (37) Buccal Mucosa, N(%) 37(100%)
Histopathology(37) Mild Dysplasia 5(13.5%)
Moderate Dysplasia 19(51.4%)
Severe Dysplasia 13(35.1%)
* Difference in sex distribution: Control vs. HNSCC, P = 0.04,
# Mean age difference: Control vs. HNSCC, P = 0.01.
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in a final volume of 25 μl human b2-microglobulin gene
(B2M) was used as control. Each sample was loaded in tri-
plicate. Relative level of gene expression was determined
by comparative threshold cycle (ddCt) method [19] after
normalization against B2M.
Immunohistochemical analysis
pRB expression was determined by immuno-staining in 5
dysplasias, 15 HNSCC samples and the two cell lines. Par-
affin sections of primary tissues and cover slip cultures of
the cell lines were reacted with 1:100 dilution of primary
antibodies (rabbit polyclonal IgG, sc-7905, for pRB [M-
153] Santa Cruz, USA, raised against amino acids 769-921
from C-terminus of pRB). HRP-conjugated (sc-2004 with
1:500 dilutions) and FITC-tagged (sc-2012 with 1:100 dilu-
tions) goat anti-rabbit secondary antibodies (Santa Cruz,
USA) were used for the primary tissues and cell lines
respectively. For permanent staining of the primary tissues,
the slides were developed using 3, 3’diaminobenzidine as
the chromogen and counterstained with hematoxylin. The
staining intensity (1 = weak, 2 = moderate, 3 = strong)
and the percentage of positive cells (<1 = 0, 1-20 = 1,
20-50 = 2, 50-80 = 3 and >80 = 4) were detected by two
observers independently and by combining the two scores,
final evaluation of expression was done (= 2 = low, 3-4 =
intermediate, 5-6 = normal, = 7 = high) [20]. The immu-
nocytochemical stained slides of the cell lines was photo-
graphed using fluorescence microscope (Nikon Eclipse
E600, Japan).
Detection of HPV-16 and HPV-18
Presence of HPV in HNSCC was detected by PCR using
primers (MY09 and MY11) from consensus L1 region
followed by typing of HPV 16/18 in L1 positive samples
as described [6].
Statistical analysis
Fisher’s exact test was used to determine different
clinico-pathological association with tumors genetic
profile, to evaluate case-control difference in distribu-
tion of genotypes and to measure the strength of
association between LIMD1 d(CA)9-38 repeat poly-
morphisms and HNSCC risk. All statistical tests were
2-sided and considered significant at probability value,
P < 0.05. Survival analysis was performed according
to Kaplan-Meier method in 50 HNSCC samples (oral
cavity n = 40, orofacial n = 4, larynx n = 4, nasophar-
ynx n = 2). Post-operative overall survival was mea-
sured from date of surgery to date of last follow-up
or death (upto 5 years). P-values were evaluated by
log-rank test for censored survival data. Significance
and relative risk of various potential prognostic fac-
tors was evaluated by Cox proportional hazards model
and the hazard ratio (HR) for each parameter with
95% confidence interval (CI) in a multivariate fashion
were estimated to predict joint impact of several
prognostic factors on overall survival of patients with
oral cavity cancer. Analysis of other sites in HNSCC
was excluded due to small sample size. All statistical
analysis was performed using EpiInfo 6.04b, SPSS 10.0
(SPSS Inc. Chicago, IL, USA).
Results
Alterations of LIMD1
To prove LIMD1 as a candidate TSG, mutation in
exon1 and exon5 of this gene was screened in 83 of pri-
mary head and neck lesions (25 dysplasias and 58
HNSCC) and two HNSCC cell lines. The deletion and
promoter methylation status of LIMD1 were screened in
these sample previously [7]. Six novel mutations were
observed in exon1 (Fig 1A-E) and one was in splice-
junction of intron4/exon5 (C deletion 3nt upstream of
exon5; Fig 1F, Table 2). Among the mutations in exon1,
one transversion with aminoacid changes at 1003C!A
(Pro335Thr; Fig 1E), three transition with aminoacid
changes at 470C!T (Ser157Phe; Fig 1A) and without
aminoacid changes at 882T!C (Thr294Thr; Fig 1C)
and 1068T!C (Gly356Gly) [7] and two frameshift
mutations due to single nucleotide deletions at 660A
(Fig 1B) and 967T (Fig 1D) were observed. Two transi-
tion mutations were overlapped with the two SNPs
(rs267237 and rs267236) (see additional file 2: Figure S1
and additional file 3: Figure legend for Figure S1.txt).
Frameshift mutations led to premature terminations of
proteins (Table 2, Fig 2). About 40% (33/83) of the pri-
mary head and neck lesions showed mutations in at
least one site. Majority of mutations were clustered in
proline and serine rich domain of LIMD1 (Fig 2). No
mutation was observed in Hep2 and UPCI: SCC084
cells. The status and pattern of LIMD1 alterations (dele-
tion/methylation/mutation) in the 83 of primary head
and neck lesions and the two HNSCC cell lines were
presented in the additional files (see Additional file 4:
Table S2 and Additional file 5: Table S3). Mutation fre-
quency of LIMD1 was low (8%, 2/25) in dysplastic lesions,
but significantly (P = 0.007) increased in stage (I+II)
tumors (42%, 8/19) (Fig 3A). Moreover, significant associa-
tion has been seen between LIMD1 mutation and its
methylation in HNSCC samples (Table 3).
Association of hmlimD1 polymorphism with risk of HNSCC
To find out LIMD1 susceptible allele, if any, associated
with HNSCC risk, we analyzed allele polymorphism of
hmlimd1 microsatellite marker in population based case-
control study. Age and sex distribution between the cases
and controls were found to be statistically significant
(Table 1). A total of 12 CA repeat alleles were observed in
our study population, ranging from 9 repeats [(CA)9] to 38
repeats [(CA)38] (Table 4). Among them, alleles (CA)17
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and (CA)19 were relatively common (>10% in frequency)
in control population. However, in cases >10% allele fre-
quency was seen in (CA)19, (CA)20 and (CA)24 alleles.
Overall, case-control difference in allele distribution was
seen to be statistically significant (P = 0.0021). Comparing
the frequency of each allele with that of all other alleles
combined, case-control differences were significant for
(CA)20 [P = 0.000005], (CA)32 [P = 0.0082] and borderline
significance for (CA)24 allele [P = 0.05427]. The (CA)20
allele was over represented in cases, whereas (CA)17 and
(CA)19 alleles were under represented in cases where
>10% allele frequency of the alleles were seen. In compari-
son to homozygous alleles distribution among cases and
controls, significant association of [(CA)20/(CA)20] allele
(P = 0.00003) was seen with the cases. Alleles (CA)32
and (CA)38 were rare in this study population.
Association of LIMD1 alterations with RB1 deletion in
HNSCC
As LIMD1 was shown to interact with pRB [8], we studied
the association of alterations of both genes. Compare to
high LIMD1 alterations, RB1 deletion was very low (27%,
22/83) in the primary head and neck lesions (Fig 3B).
Deletion frequency of RB1 was low in dysplastic lesions
(8%, 2/25) and significantly (P = 0.045) increased to stage
(I+II) tumors (32%, 6/19) consistence with our previous
findings [13,14] (Fig 3B). No association between LIMD1
alterations and RB1 deletion was observed, however co-
alteration of both genes was high (33%, 13/39) in the stage
III+IV of head and neck lesions (Table 5).
Comparison in the mRNA expression of LIMD1 and RB1
Quantitative RT-PCR analysis revealed high reduction of
LIMD1 mRNA expression (25.1 ± 19.04) than RB1 (3.8 ±
8.09) (Fig 4). Reduced mRNA expression of LIMD1
showed significant correlation with the gene’s methylation
(see Additional file 6: Table S4). Half of these tumors (12/
24) showed mean fold reduction in LIMD1 expression
compare to 21% (5/24) in RB1. In Hep2 and UPCI:
SCC084 cells RB1 expression was comparable to the nor-
mal tissues than that of reduced LIMD1 expression.
Immuno-staining of pRB
In normal epithelium, immuno-staining revealed intense
nuclear and cytoplasmic pRB expression at basal layer,
followed by gradual low cytoplasmic expression in dif-
ferentiated cells (Fig 5). In dysplastic lesions as well as
in HNSCC, both nuclear and cytoplasmic expression of
pRB was observed. Low/medium level of pRB expression
Figure 1 SSCP autoradiographs and respective chromatographs with resulting aminoacid sequences of representative
samples showing mutations in LIMD1 exon 1 (A-E), and exon5 (F). Arrows indicated shifted bands and nucleotide changes. T, Tumor;
N, corresponding normal.
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Table 2 Summary of LIMD1 mutations
Mutations
Exon1 Exon5
Nucleotide change 470C ! T 660A del 882C ! T 967T del 1003C ! A 1068T ! C C del at intron4/exon5
TNM stage Amino acid change Ser157 Phe Frame shift Thr294Thr Frame shift Pro335Thr Gly356Gly Splice-juction
Samples showing
mutations
Moderate L66 - - - - - - -
Moderate L139 - - SNPa - - + -
Severe L144 - - SNPa - - - -
Severe L126 - - SNPa - - + -
Severe L153 - - SNPa - - - -
StageI #292 - - SNPa - - - -
StageI #2642 - - - - - + -
stageII #2772 - - + - - - -
stageII #7216 - - - + - - -
stageII #2073 + - SNPa - - + -
stageII #5303 - + - - - - -
stageII #1234 - - SNPa - - SNPb -
stageII #2323 - - + - - - -
stageII #1108 - - - - - + -
stageII #7077 + - - - - - -
StageIII #821 - - - - - + -
StageIII #1367 + - - - - - -
StageIII #1552 - - SNPa - + - -
StageIII #615 - - - + - - -
StageIII #5090B - - + - - - -
StageIII #816 - - + - - - -
StageIII #326 - + SNPa - - - -
StageIII #1068 - - SNPa - + - -
StageIII #3893 - - - + - - -
StageIII #308 - + SNPa - - - -
StageIII #6433 - + SNPa - - - -
StageIII #1332 + - SNPa - - - +
StageIII #2398 - - - + - - -
StageIII #7059 - + - - - - -
StageIV #1087 - - + - - - -
StageIV #4075 - - - - - SNPb -
StageIV #2508 - + - - - + -
StageIV #5114 - - + - - - -
StageIV #5219 - + - - - - -
StageIV #1084 + - - - - SNPb -
StageIV #5184 - + - - - - -
StageIV #944 - - - - - - +
StageIV #2785 - - SNPa - - - +
StageIV #1774 - - - - - + -
Cell lines Hep2 - - SNPa - - SNPb -
SCC084 - - SNPa - - SNPb -
Mutation frequency in HNSCC 6% (5/85) 9% (8/85) 7% (6/85) 4% (4/85) 2% (2/85) 9% (8/85) 4% (3/85)
SNPa: rs267237; SNPb:rs267236; del: deletion; L: Dysplastic lesions; #: Invasive samples; ‘+’: Presence; ‘-’: Absence.
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was observed in 30% (6/20) of head and neck lesions
contrary to frequent LIMD1 alterations (Table 6). In
HPV18 positive Hep2 cells, pRB expression was mainly
in cytosol, whereas in UPCI: SCC084 (HPV negative), it
was expressed both in nucleus and cytoplasm. Concor-
dance was seen between RB1 deletion with its RNA and
protein expression (Fig 5).
Clinical and prognostic implications of LIMD1 and RB1
alterations
Using L1 primer, HPV DNA was detected in 56% (82/
147) of head and neck lesions of which 84% (69/82)
were HPV-16 positive, 11% (9/82) were HPV18 positive
and the rest 5% (4/82) were positive for both HPV16/18.
Univariate analysis showed significant association of RB1
Figure 2 Schematic diagram of LIMD1 gene and protein with mutational hotspot. Termination1,2represented premature termination of
LIMD1 protein after 7aminoacids and 2 aminoacids respectively. Aminoacids 404-442: Reported pRB binding region [8].
Figure 3 (A). Patterns of LIMD1 molecular alterations during HNSCC progression. Bars correspond as follows: *: indicated the level of
significance. [Checkered line] Deletion; [brick patterned line] Methylation; [grey spotted line] Mutation. (B). RB1 deletion pattern in progression of
HNSCC. Bars correspond as follows: [Checkered line] Dysplastic lesions; [brick patterned line] Stage I+II; [grey spotted line] StageIII+IV; *: indicated
the level of significance.
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deletion with HPV negativity (P = 0.02 for dysplastic
lesions; P = 0.01 for HNSCC).
Log-rank test revealed significant poor survival in
patients having alterations in at least one of these
genes (Fig 6). Patients with both LIMD1 and RB1
alterations showed worse prognosis and absence of
RB1 alterations did not change patients’ survival con-
siderably (Fig 6). Multivariate analysis showed that
LIMD1 molecular alterations (P, 0.03; HR, 4.5; CI, 1.1-
17.8) along with tobacco addiction (P, 0.05; HR, 4.5;
CI, 0.96-20.8) in absence of HPV (P, 0.05; HR, 0.28;
CI, 0.08-0.99) were significant predictor for poor sur-
vival of patients with oral cavity cancer (Table 7).
Moreover, patients with advanced grade tumor (P,
0.50; HR, 1.49; CI, 0.46-4.89) having nodal metastasis
(P, 0.42; HR, 1.63; CI, 0.49-5.34) along with RB1 dele-
tion (P, 0.15; HR, 2.27; CI, 0.74-7.02) showed a trend
to have poorer survival, albeit being statistically
insignificant.
Discussion
Differential alterations of LIMD1 and RB1 during HNSCC
development
To understand the role of LIMD1 and RB1 in HNSCC
development, alterations of these genes were analyzed in
25 dysplastic lesions of head and neck, 58 HNSCC sam-
ples and two HNSCC cell lines. In dysplastic lesions
LIMD1 mutations was less frequent than deletion and
methylation (see Additional file 4: Table S2 and Addi-
tional file 5: Table S3). However, during progression of
the tumor comparable frequencies of these alterations
were seen, suggesting the deletion and methylation of
LIMD1 as early events in this tumorigenesis. About 80%
(67/83) of the samples showed any two of the alterations
Table 3 Association study of LIMD1 different molecular
alterations
Dysplastic lesions HNSCC
Del+ Del- P Del+ Del- P
Meth+ 11 8 0.7022 21 15 0.6887
Meth- 4 2 14 8
Mut+ 1 1 0.7634 18 13 0.7036
Mut- 14 9 17 10
Mut+ Mut- Mut+ Mut-
Meth+ 1 18 0.3694 15 21 0.02139
Meth- 1 5 16 6
Del: Deletion; Meth: Methylation; Mut: Mutation; ‘+’: Positive; ‘-’: Negative.
Table 4 Allele frequency of (CA)n polymorphism in the LIMD1 gene in head and neck cancer cases and control
Allele No of (CA)n repeats Case Control P#
No. of alleles % No. of alleles %
(CA)9 9 7 2.38 11 2.94 0.6571
(CA)13 13 4 1.36 35 9.36 0.00012
(CA)17 17 23 7.82 46 12.29 0.0592
(CA)19 19 97 32.99 169 45.19 0.00139
(CA)20 20 66 22.45 36 9.63 0.000005
(CA)21 21 21 7.14 15 4.01 0.075134
(CA)24 24 30 10.2 23 6.15 0.05427
(CA)26 26 2 0.68 15 4.01 0.0067
(CA)27 27 19 6.46 13 3.48 0.0728
(CA)30 30 10 3.4 6 1.6 0.1316
(CA)32 32 14 4.76 5 1.34 0.0082
(CA)38 38 1 0.34 0 0 0.259
Total no. of alleles 294 100 374 100
c2 = 29.175, df = 11, P = 0.0021
Genotype Case % Control % P#
(CA)17/(CA)17 6 9.23 11 15.94 0.2434
(CA)19/(CA)19 33 50.76 56 81.16 0.0002
(CA)20/(CA)20 19 29.23 2 2.89 0.00003
(CA)21/(CA)21 5 7.69 0 0 0.0247
(CA)24/(CA)24 1 1.54 0 0 0.4851
(CA)32/(CA)32 1 1.54 0 0 0.4851
# From Fisher’s exact test.
OR, Odds ratio
CI, Confidence interval
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in LIMD1 supporting the modified Knudson two hit
hypothesis as a candidate TSG. High frequency (94%,
78/83) of LIMD1 alterations (deletion/methylation/
mutation) than RB1 was seen in the samples. Majority
of mutations in LIMD1 were present in and around the
pRB binding domain of exon1. Unlike us, Huggins et al.
detected very low frequency (4%, 6/165) of mutation in
exon1 of LIMD1 at different positions in breast carci-
noma [21]. In our samples, about 42% (14/33) of the
mutations produced non-functional truncated LIMD1
Figure 4 (A). Quantitative RT-PCR analysis showing LIMD1 and RB1 expression in HNSCC samples (n = 24), Hep2 and UPCI: SCC084 cell
lines. Bars represented the gene expression normalized to b2-microglobulin and relative to normal counterpart. Black bar represented RB
expression and cross line filled bar represented LIMD1 expression.
Figure 5 Immunohistochemical staining patterns of pRB in dysplastic lesions (L), HNSCC samples (T), normal tissues (Normal) and
HNSCC cell lines (Hep2, UPCI: SCC084) samples showing high (a), low/negative (b) expression of pRB protein (indicated by arrows). In
#797T, RB1 was not deleted whereas in #944T, this gene was deleted. The regions marked within the circle (20×) were magnified to 40× at inset.
Table 5 Association study of LIMD1 alterations with RB1
deletion
LIMD1
Dysplasia Stage I+II Stage III+IV
ALT+ ALT- ALT+ ALT- ALT+ ALT-
RB1 Del+ 2 0 7 0 13 0
Del- 21 2 11 1 24 2
P 0.6637 0.4326 0.3046
Alt: Overall molecular alterations; Del: Deletion; ‘+’: Positive; ‘-’: Negative.
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proteins due to premature termination or splice-junc-
tion mutations (Table 2). The significance of synon-
ymous mutations at two SNPs was not clear.
RB1 deletion was infrequent with much lower fre-
quency in dysplastic lesions than invasive samples, sug-
gests it less likely to be a candidate TSG in this tumor.
Similar to other reports [22], there was a strong associa-
tion between RB1 deletion and reduced pRB expression
in our samples (P = 0.0006) (Table 6), indicating dele-
tion as the main cause of RB1 inactivation. The differen-
tial downregulation in mRNA expression of LIMD1 and
RB1 was concordant with their molecular alterations,
reflecting genetic imbalances transmitted in transcript
level. Intense pRB staining in basal layer of normal
epithelial of oral cavity compare to the differentiated
cells indicates differential regulation of pRB during dif-
ferentiation. Similar reports were also found in normal
epithelium of esophagus and cervix [23-25]. LIMD1
staining has not been done due to unavailability of com-
mercial antibody. In dysplastic lesions and in HNSCC,
pRB expression was seen both in nucleus and cytoplasm
where RB1 deletion was absent, similar to basal layer of
normal epithelium. However the functional status of
pRB in tumor cells is not clear. The reduced level of
LIMD1 in tumor cells might destabilize the pRB-E2F
interaction and chromatin remodeling complex, result-
ing deregulation of cell cycle.
Identification of susceptible allele of LIMD1
As LIMD1 has been suggested to be a candidate TSG in
HNSCC, our next attempt was to search for a suscepti-
ble allele of this gene, if any, associated with HNSCC
risk. The case-control study identified (CA)20 as the risk
allele both in its homozygous and heterozygous state for
HNSCC development. Similar repeat length polymorph-
ism in upstream of several genes has been reported
[26-28]. The significance of the (CA)9-38 repeat varia-
tions at upstream of LIMD1 was not clear. Regarding
the conformation, the (CA)19 repeat length might be a
critical point. Though the significance of critical (CA)20
Table 6 Correlation between mRNA and protein expression of RB1 and their association with LIMD1 molecular
alterations.
RB1 LIMD1
Sample No.; HPV status Genetic alterations mRNA status Protein expression Genetic/epigenetic alterations mRNA status
Dysplastic lesions
L127; HPV- D- ND Normal D+Me+Mu- ND
L139; HPV- D- ND Normal D-Me+Mu- ND
L154; HPV- D- ND Normal D+Me+Mu- ND
L162; HPV- D- ND Normal D+Me+Mu- ND
L158; HPV16 D- ND Medium D+Me+Mu- ND
HNSCC samples
#1004; HPV- D- Normal Normal D+Me+Mu- ↓
#5165; HPV- D- Normal Normal D+Me+Mu- ↓
#6817;HPV16 D+ ↓ Medium D+Me+Mu- ↓
#2884; HPV- D- Normal Normal D-Me-Mu- Normal
#1108; HPV - D+ ↓ Medium D-Me+Mu+ ↓
#1774;HPV16 D+ ↓ Low D-Me+Mu+ ↓
#872; HPV- D- Normal Normal D-Me-Mu- Normal
#5303; HPV- D- Normal Normal D-Me+Mu+ ↓
#6907;HPV16 D- ↓ Low D-Me+Mu- ↓
#1087; HPV- D- Normal Normal D-Me-Mu+ Normal
#944; HPV- D+ ↓ Low D+Me+Mu+ ↓
#5733;HPV16 D- Normal Normal D+Me+Mu- ↓
#6392; HPV- D- Normal Normal D-Me+Mu- ↓
#7077; HPV- D- Normal Normal D-Me-Mu+ ↓
#797; HPV- D- Normal Normal D+Me+Mu- ↓
Hep2, HPV18 D- Normal Normal D-Me+Mu- ↓
UPCI:SCC084, HPV- D- Normal Normal D-Me+Mu- ↓
L: Dysplastic lesions; # HNSCC samples; D: Deletion; Me: Methylation; Mu: Mutation; ‘+’: Positive; ‘-’: Negative; ‘↓’: Down expression; ND: Not done.
Ghosh et al. Molecular Cancer 2010, 9:58
http://www.molecular-cancer.com/content/9/1/58
Page 10 of 13
repeat as risk for this tumor development is not fully
understood, it seems that this repeat length might desta-
bilize Z-DNA conformation, causing transcriptional
repression of LIMD1. Similar effect might also be
imposed by (CA)21-(CA)38 alleles, but due to their low
prevalence in our study population, statistical signifi-
cance has not been observed. In light of the strength of
associations and the increased risk for HNSCC, further
research is warranted to explore the potential underlying
mechanism(s) involved.
Association of LIMD1 and RB1 alterations with HNSCC
progression and prognosis
Unlike methylation and deletion, significant association
of LIMD1 mutation with tumor progression indicates
that mutation might have some additive effect in inacti-
vation of this gene. In multivariate analysis, association of
LIMD1 alterations along with tobacco addictions HPV
negativity and poor patients’ outcome suggests LIMD1 as
predictive clinical marker in progression of HNSCC.
Agreed with similar findings [29-31], significant associa-
tion was seen in RB1 deletion with HPV negative samples
and with HNSCC progression. Likewise, a trend towards
significance of RB1 deletion in advance grade tumors,
with nodes of pathology has also been observed [31].
However, worse prognosis of the patients having both
LIMD1 and RB1 alterations suggests RB1 inactivation
might have some synergistic impact in HNSCC develop-
ment. Comparatively better survival of patients with
LIMD1+RB1- (LIMD1 unaltered &RB1 deleted) than
LIMD1-RB1+ (LIMD1 altered &RB1 unaltered), indicates
LIMD1 as a key regulator of the disease.
Conclusion
Thus, it can be concluded that LIMD1 is a susceptible
gene for HNSCC development and its alterations, alone
or with RB1 alterations acts as an important prognostic
marker in this cancer.
Figure 6 Kaplan-Meier 5-year survival probability curves with cumulative survival of HNSCC patients by molecular alteration status in
LIMD1 and RB1 loci. Solid line represented survival probability without molecular alterations of these two genes (wild type, denoted as ‘+’) and
dashed line represented the same probability with molecular alterations of either of these genes (’-’ indicating altered state). n, total number of
HNSCC samples studied in each case.
Table 7 Multivariate analysis of overall survival of oral
cavity cancer patients with different clinicopathological
parameters.
Variable Overall survival
P-value Hazard ratio(HR) 95% CI for HR
LIMD1 alteration 0.0318 4.51 1.14-17.82
RB deletion 0.1535 2.27 0.74-7.02
Stage 0.5144 0.79 0.39-1.59
Grade 0.5044 1.49 0.46-4.89
Age 0.7786 0.84 0.25-2.85
Node 0.4228 1.63 0.49-5.34
HPV 0.0498 0.28 0.08-0.99
Tobacco 0.0559 4.49 0.96-20.89
Alcohol 0.2659 0.29 0.03-2.52
CI, Confidence interval.
Bold letters represent significance level.
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Additional file 5: Pattern of LIMD1 alterations in HNSCC during
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frequencies of deletion, methylation and mutation during the
progression of HNSCC.
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Additional file 6: Correlation between LIMD1 methylation and
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